This round is no longer accepting investments, but hundreds just like it are live now.

Log In

INVEST IN MEDANSWERS TODAY!

Innovative Infertility App

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$145,702.50 Raised

REASONS TO INVEST

ABOUT

HEADQUARTERS

TEAM

Alice Crisci
Alice Crisci
Chief Executive Officer

Alice Crisci is a cancer survivor, entrepreneur, author and activist. She founded Ovum Medical as a science and technology company to solve health care problems through technology. Their first product MedAnswers helps infertile people in crisis connect with the specialist they need. She also founded the oncofertility charity, Fertile Action, three weeks into her breast cancer diagnosis at 31-years-old. She published her first book, "Too Young for This," a few days before her double mastectomy. As Director of Government Affairs and Patient Advocacy for the California Cryobank, a reproductive tissue bank, from 2012 - 2015, Ms. Crisci established regulatory relationships across multiple sectors and within both the US Congress and California Legislature. Her firm, Ovum Medical, is the only group tracking legislation for gamete banks across the country. Ms. Crisci also co-built a revenue acceleration consulting firm in her 20's that sold to the oldest direct selling company in the nation. Her subsequent consulting company called Beeline Global, accelerated growth for start-ups and companies between $10 and $25M in revenue but was sidelined by her cancer diagnosis. She is currently a strategic advisor to other start-ups in the health tech space including oncology companies, genomics ventures and educational institutions. She is the ecstatic mom of a fertility preservation miracle son who at three-years-old calls himself a scientist and the future owner of MedAnswers. Aptly named Dante, meaning enduring, they reside in Southern California with their stray cat named Josh and Shih Tzy Nay-Nay. Ms. Crisci has been featured in major publications across the world and on national television shows like The Doctors and The Today Show.

Santiago Munne, PhD
Santiago Munne, PhD
Scientific Co-Founder

Dr. Santiago Munné, Ph.D is a reproductive geneticist who developed the first Preimplantation Genetic Diagnosis (PGD) test to detect embryonic numerical chromosome abnormalities to avoid Down’s syndrome and other abnormalities. He co-founded Reprogenetics in 2000 to expand PGD services to Europe, Japan and South America. His team has performed over 80,000 PGD cycles for chromosome abnormalities to improve IVF outcomes with over 300 research publications. He is a frequent lecturer, both nationally and internationally, on his team's work in the field of Preimplantation Genetics. He exited Reprogenetics US and UK, a company as CEO in 2016 when he sold to CooperSurgical. He also co-founded Recombine, a reproductive genetics company for carrier screening and a breakthrough genetic test called FertilityMap in 2014, which he sold to CooperSurgical for $85M in 2016. He co-founded the spinout of Recombine, Phosphorus, a computational genomics venture, in August, 2016. Dr. Munne is currently CSO of CooperGenomics and co-founder of MedAnswers. Originally from Barcelona, Dr. Munné gained his Ph.D. in genetics from the University of Pittsburgh. He is also the proud father of two daughters.

Carter Freeman

Carter Freeman

Consulting CFO

An accomplished professional with over 25 years of senior-level financial and accounting experience, Carter has demonstrated an ability to embrace new situations, establish trust and develop a workable game plan. Carter's capabilities encompass negotiating ownership transition leading and supporting capital raising efforts totaling over $100 million, participating in multiple acquisitions from both the buy- and sell-side, in addition to merging operations as acquirer and acquiree.

Sebastian Castillo

Sebastian Castillo

CTO

Sebastian Castillo is a computer scientist with a background in systems engineering and dynamic languages. He was responsible for paymentez. He led growth from zero to 1.3M active users and 1.2k hits per second; and $0 to $300m. He was responsible development (Java) and backend (python) for Colombia's largest ISP; lead for the health care payments system for all of Colombia, with 32 Linux servers including firewall, db, load balancer deployments, and led security of Bancolombia using Sabsa.

David Alzate

David Alzate

VP, Technology

David holds a degree in System Engineering from EAFIT, and also a Master degree in Entrepreneurship and Innovation Management from KTH (Sweden). David is an ardent proponent and teacher of the Lean Startup methodology and SCRUM. He recently launched his first iOS app (servirank) using Apple's new programming language (Swift), as a personal project. David has lived and worked in the US, Colombia, India and Sweden, and excels at managing multicultural environments.

Lori Sanford

Lori Sanford

Consulting Senior Controller

Lori is a seasoned finance and operations executive with more than 30 years of finance, accounting and operational experience. Particular strengths include M&A, due diligence and audit support, software implementation and conversions, and the establishment of financial and business policies and best practices. She also assists us with funding acquisition, investor relations, budgets and forecasts, corporate governance, process reengineering and other complex accounting issues.

Catherine Welch, MBA

Catherine Welch, MBA

Dir. Expert Engagement - US

Catherine Welch is an accomplished clinical embryologist with over 14 years of experience in the IVF field. She is dedicated to reproductive genetics, specifically preimplantation genetic testing and carrier screening technologies. She has participated as an speaker instructor for many of Illumina’s KOL summits and trophectoderm biopsy workshops and Catherine lives in Southern California with her husband and four children.

Demián Glujovsky, MD

Demián Glujovsky, MD

Dir. Expert Engagement - LATAM

Dr. Demián Glujovsky is an internationally renowned specialist in reproductive medicine, overseeing Latin American expansion. Since 2005, he is part of the medical staff at CEGYR, Buenos Aires, Argentina. Dr. Glujovsky has been trained in two recognized reproductive centers in the United States: Reproductive Medicine Associates (RMA) of NJ and the Center for Women’s Reproductive Care at Columbia University in NYC.

Katherine Wu

Katherine Wu

Dir. Regulatory Affairs

Katherine Wu oversees the regulatory path for the groundbreaking app, MedAnswers in the US, Latin America and Europe. Katherine holds a BS in Molecular, Cell, and Developmental Biology and a minor in Political Science from UCLA and has worked with patients, doctors, researchers and scientists to help deepen the knowledge and broaden our understanding on some of the world's most prevalent diseases.

Sebastian Arcila

Sebastian Arcila

Engineer

Sebastian Arcila is a multiple winner of ACM-ICPC challenges. He recently left CECI at MIT in Cambridge, and also has degrees from EAFIT, in Systems engineering, Math, Algorithms, and Data Structures. Most recently, he was one of the first engineers at WeHeartIt where he scaled the application to 25m users. Previously, he was a lead engineer at numerous well-known startups: Authy, TopTal, Art.sy, and Stackbuilders.

Juan Felipe Arango

Juan Felipe Arango

Web Developer

Passionate Web Developer with a strong sense of design concepts and UX, he holds a degree in System Engineering from EAFIT University and also a Minor degree in Design. Rails and JS lover, Juan Felipe loves to work on both (front-end and back end) sides of a project and also serve as a bridge between design teams and development teams. In free time he can be found trying to improve some development process, learn something new or exercising.

Oscar Rendon

Oscar Rendon

Engineer

Experienced Software Engineer, operating on the entire software life cycle, from conception to product release. Solid background in software design and software architecture. Oscar worked with C#/.NET stack, but now with Ruby and Elixir/Erlang. He loves exploring new languages, and as such, Oscar is also versed in Clojure, Elixir/Erlang (and Golang). He also co-organizer of Ruby Medellin meetup, Rails Girls workshops, and RubyConfCo conference.

Daniel Gomez

Daniel Gomez

Android Developer

As lead mobile engineer, Daniel oversees both the product roadmap on all mobile devices but also works in the trenches with my team developing primarily for Android. Previously Daniel has experience in projects on both the backend and client (doing native app development). He has worked at ISF de Colombia, MakinGIANTS, Fabrica Digital, Eafit University -- where he also did my undergraduate studies in Systems and Computer Engineering.

Santiago Bustamante

Santiago Bustamante

iOS Developer

Santiago Bustamante is an engineer who absolutely loves all new technologies (except Microsoft). With several years of experience developing native iOS games and applications both in academic and professional projects, he has experience developing REST APIs for communicating with the client and the server. Santiago has participated in multiple projects and have significant experience personally and professionally working both individually and on a team.

Justin Chung

Justin Chung

Consulting UX/UI Designer

Justin has extensive experience in designing various forms of visual communication and UX/UI, helping small to medium sized agencies, startups, and inspired individuals. He also has a solid background in marketing and advertising, leading the strategic development of multiple fortune 500 clients such as AT&T, Cosmopolitan of Las Vegas, JPMorgan Chase and Toyota Motor Sales for their diversity market efforts.

Gloria Tesch

Gloria Tesch

Social Media Marketer

Gloria Tesch is a published author, model and advocate with a robust social media following. She published two novels at the age of thirteen, earning her the distinction of being the world’s youngest novelist. 'Maradonia and the Seven Bridges' and 'Maradonia and the Escape from the Underworld', set up a sweeping epic journey into a fantastical world of magic and power. By 15, she published her first five books.

Alexander Bisignano

Alexander Bisignano

Investor and Advisor

Alexander Bisignano is the Founder and CEO of Phosphorus, a computational genomics company. He also co-founded and exited Recombine for $85M. Alex is a seasoned computer programmer with experience developing complex web applications and providing high-end bioinformatic solutions for molecular genetic data. He advises Ovum Medical on business strategy, fundraising and investor relations.

TERMS

MedAnswers
Overview
DEADLINE
Jan 25, 2018
Breakdown
OFFERING TYPE
Equity

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets

$268,019

$85

Cash & Cash Equivalents

$266,519

$85

Accounts Receivable

$0

$0

Short-Term Debt

$0

$0

Long-Term Debt

$350,000

$0

Revenue & Sales

$0

$0

Costs of Goods Sold

$0

$0

Taxes Paid

$0

$0

Net Income

-$176,882

$0

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000:

PRESS

Article Image
'Unstoppable' Mom, Cancer Survivor Creates New Fertility App

Alice Crisci did. Unlike the rest of us who'd had such problems, she decided to do something about it. She founded Ovum Medical to provide MedAnswers, an iPhone app that gives patients direct access to doctors and other experts to answer questions.

Article Image
KAHI Radio with MaryJane Pop

MaryJane Pop of KAHI AM 950 talks to Alice Crisci of MedAnswers.

Article Image
Digital Health App MedAnswers Seeks Funds Through Reg CF Round on StartEngine

MedAnswers, a digital health app that at first connects infertility patients to experts for on-demand questions and answers, announced on Thursday the launch of its Reg CF campaign. As a cancer survivor, single mom and medtech entrepreneur, Crisci was in search of alternative sources of seed funding

Article Image
Dr. Google Calling MedAnswers: An interview with Alice Cresci

Crisci is also the founder of MedAnswers, a digital health app that connects anonymous patients, to board certified experts in various medical disciplines for personalized question and answer sessions.

Article Image
MedAnswers Announces Securities Crowdfunding Seed Round

We love the idea of inviting the same people who need to use our product to be investors. We recognize traditional investors might push back on this, but we are proud of our offering and believe in democratizing private fundraising

ALL UPDATES

01.23.18

Thank you all!

Is it too late to say Happy New Year? :)

I started writing handwritten holiday notes to each of our investors and got side tracked by a few things. So handwritten thank you notes will be coming your way instead soon. 

Last year was a WILD ride and I want to THANK YOU for jumping on board with us. It's hard to believe we launched our platform just last June. Next month, we are launching our nutrigenomics product integration with a prestigious personal genetics CLIAA certified lab. 

We are making good on the promise to bring personalized fertility solutions to those struggling to have their family. And we're very excited to start reporting revenue numbers to all our investors hopefully in March. From the bottom of my heart, thank you for supporting us at a critical time in our company's history. We completed this historic equity crowd raise and have also been very successful in assembling a Reproductive Council of infertility investors. They are active answering questions on the app and advising us. Tomorrow, I start prepping for our Series A raise targeting the VC community. 

We relocated the company (and my little family) up to the Bay area to participate in an accelerator program and meet as many investors as possible. We're about a mile away from our lab partner too. 

We have over 1,500 users and almost 100 experts! Our nutrigenomics product will provide actionable insights to patients who can make lifestyle changes to improve their chances at a successful natural or IVF cycle. I truly can't wait for this product and the difference we can make empowering our users. 

We will provide on-going reporting and communication to you (either through the startengine campaign or through our back-end privately)- feel free to always reach out to me personally! alice@medanswers.com 

Thank you and I hope 2018 is off to an incredible start for each of you as it is for us! 

With immense gratitude, 

Alice (and the team) 

10.31.17

AMAZING NEWS!!!!

Last Thursday, I received the kind of news that makes even the toughest entrepreneur weep: MedAnswers was accepted into a very, prestigious accelerator program. While I can't disclose which one until we clear due diligence (not a problem I cleared the rigorous StartEngine one!), I can tell you this: An accelerator comes with mentors, tools and the capital we need to catapult to success. 

Not only was our idea validated, but so were our precision tools. And I was validated as a leader, something none of us want to admit we may need in startup land. The thing I am MOST enthused about (beyond the reality that this will increase the valuation of our company so hooray for our early investors) is that I get to bring MY AMAZING TEAM'S WORK TO THE WORLD. 

Together, we will not fail. 

If you were considering an investment, now would be a good time. 

With enthusiasm and gratitude,

Alice 

10.13.17

3rd Closing

Per the offering terms, and because our equity crowdfunding campaign has now cleared additional investors, MedAnswers has decided to conduct a closing 5 days from today. If your funds have cleared, you will have up until 48 hours prior to this closing to cancel your investment. If your funds have not yet cleared by this date, then you will be part of the next closing if and when your funds do clear. 

Thank you so much! 

Alice 

10.09.17

MedAnswers Progress

Greetings investors, supporters and followers! 

I’ve just returned from a whirlwind work trip for MedAnswers. I met with potential investors, geneticists and collaborators. During that time, I finalized an option agreement for a pharmacogenomic and nutrigenomic product integration. This is our greatest competitive differentiator to date. In fact, no other digital health tool has a genomics angle so far. We are developing the most comprehensive, precision medicine tool for the fertility field! The difference we will make for patients trying to get pregnant and those going through an IVF cycle is very exciting! We will keep our investors closing informed of our progress and expect to go to market with this product, integrated into the MedAnswers platform, sometime next year. 

As you probably noticed, we raised our offering to the maximum allowed by the SEC. We had too many potential investors disappointed they did not make it in the first round, we wanted to give them an opportunity to join us. We also extended the offering for four months so it crosses two different tax years. Also of note: Startengine recently rolled out a new product that would allow investors who have shares for at least one year to sell those shares. While we hope all investors hold their shares until the company exits, this could be a good option for some. We do not know much about this new product yet or how it relates to us specifically, but we will learn as much as we can to keep you informed. 

We have many exciting product developments underway so we hope if you are considering an investment, you will do so soon! 

The product is constantly improving! We do have an Android version ready for release, however, I am holding off to deploy because maintenance on two native products is expensive. With the latest iOS release, I learned each platform release creates bugs for all our apps. We have to work very quickly to solve the bugs so our users and experts do not get upset. With that in mind,  we are pushing forward on a fully-functioning WEB APPLICATION! It will work on both mobile and desktop views; and does not come with bug issues like native apps. Our experts are thrilled with this option. All users will be able to use it! It will be ready in 30 - 45 days. In the meantime, our users can search for questions already asked on the app using our web search tool. They must register before reading the answers. We are committed to the free version of the product, but also need to protect the content our patients and experts created together. We have other ways to SEO our company than publicly sharing all content too readily. 

Our digital marketing team is doing an amazing job! Our cost per download is at an all-time low of $2.80/download. We are very pleased with this and expected to continue to get lower as we deploy other social media channels with rich content and inspiration. As you will recall in our proforma, we know if we can spend $150,000 on acquiring users, we will have enough of a user base (more than 41,000) to begin monetizing the product - the faster we self-sustain, the better for all of us! We hope with the new investors joining us through the startegine campaign, we can acquire these users in November and December. 

We have 86 registered experts and are meeting with many of them at the annual ASRM (American Society for Reproductive Medicine) conference in San Antonio at the end of October to ensure we implement their important feedback. 

A few weeks ago, the New York Magazine posted a misleading article on PGS. They misquoted my co-founder, Dr. Santiago Munne, mixed up terms and used an old technology as “proof” of the author’s position, that could not detect the very thing the author was trying to report on. Confused yet? So were our patients. The MedAnswers community responded with a lead response from Dr. Munne, along with comments and upvotes by our expert community. It was so long, it launched our blog. This is exactly why we exist - now our patients can read a post knowing our trusted expert community has weighed in. I am very grateful to all of them and relieved we were able to clear up some of the confusion so quickly. Read the full piece here: blog.medanswers.com 

It’s a goal of mine to post more updates as we continue to march forward so expect to hear a bit more frequently from me. 

With immense gratitude,

Alice 





09.26.17

Amending our Securities Offering

Hello! Recently, a change was made to the MedAnswers offering. Here's an excerpt describing the specifics of that change:


MedAnswers has adjusted the maximum funding goal to $1,070,000 and extended the end date of the offering.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

09.11.17

2nd Closing!

Per the offering terms, and because our equity crowdfunding campaign has now cleared additional investors, MedAnswers has decided to conduct a closing 5 days from today. If your funds have cleared, you will have up until 48 hours prior to this closing to cancel your investment. If your funds have not yet cleared by this date, then you will be part of the next closing if and when your funds do clear. 

Thank you so much for supporting this exciting venture! 

08.18.17

Offer Closing!

MedAnswers has exceeded our minimum funding goal and will continue to accept investments through 09/25/17.

Per the offering terms, and because our equity crowdfunding campaign has now exceeded the minimum funding goal, MedAnswers has decided to conduct a closing 7 days from today. If your funds have cleared, you will have up until 48 hours prior to this closing to cancel your investment. If your funds have not yet cleared by this date, then you will be part of the next closing if and when your funds do clear. 

08.11.17

Finishing the Week Strong!

When I was a high-school basketball player, Coach Barb, used to say to me, "You have to finish strong Alice." I would often steal the ball and sprint so fast for a layup, I was sometimes not in control. I would replay her words as I went in for a layup or stood at the free throw line. Some of my best lessons in life came from playing basketball and being coached by her. 

This week we are finishing strong! 

Key investors across the world, including a couple high school friends, helped us achieve 276% of our low goal and 26% of our primary goal. In basketball, you only have one goal: to win. So our team is focused on that $107,000 and getting it across the finish line by wed of next week. 

Why wed when we have more than a month left in this campaign? 

We think it sends a powerful message to our patients, our team and the world that we can hit our goal within three weeks of the campaign being open. 

Thank you for believing in us and if you haven't taken the plunge yet, consider doing it by Monday. 

Join the Team Who Finishes Strong. 

Toward Vision and Victory,

Alice 

08.10.17

What a Day!

We had a great day on our campaign today - thanks to a big bump, I'm heading into a Forbes interview tomorrow with incredible momentum and confidence in our collective ability to accomplish our goals. We truly have the best team hard at work to keep MedAnswers FREE for users! Thank you investors for supporting our mission and vision. Welcome to the MedAnswers Family! 

If you want to listen to how we intend to expand into Oncology, here is an interview I did with the Oncozine brief: https://beta.prx.org/stories/212489 (ignore how he spelled my name, he was lovely to speak with). 

We were also featured in TechCompany News. http://techcompanynews.com/digital-health-startup-medanswers-provides-patients-direct-access-to-medical-experts/

Tomorrow, Forbes! 

Towards Vision and Victory, Alice 



08.08.17

Thank you!

I wanted to take a moment, as are almost two weeks in, to say thank you to our early investors! While we've been actively promoting this campaign, we also were busy doing a critical marketing test to determine our actual price / customer acquisition. 

We built our financial model around a high customer acquisition cost. We assumed we would have to spend $20 - $50 to acquire a single user. We were wrong! In actuality, we are acquiring our new users between $2.40 and $2.70 /user. 

This is great news for our investors! We know that cost can fluctuate up and down, but it is a great leading indicator of the scalability of this model. Our first year goal is to help the first 41,000 users get the answers they need about infertility. And we can help them for a customer acquisition cost of around $100,000. 

So from the bottom of my heart, thank you investors for your commitment to getting MedAnswers to the patients who need us. 


REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into MedAnswers.

JOIN THE DISCUSSION

0/2500

SP
SuZan Powell

5 years ago

I find this very interesting as someone who has been dealing with infertility for two years now. Two things, when I searched for fertility or infertility in the app store, this app did not appear, at least in the first apps 20 apps that popped up, are their plans to optimize the search so that the app is higher up? The second issue I see is that I typed in Med Answers, with a space and the app did not appear. When I typed it in as all one word, it appeared. I do not know much about app development, but I would guess that as an app, you would want to be found in all variable searches. Any insight into the search function to find the app for users who don't necessarily type in MedAnswers directly?

0

0

PA
Prasanna Airody

6 years ago

Hi Alice, How is MedAnswers different from Kindara Inc, which is addressing reproductive health and fertility which went for crowdfunding on SeedInvest platform? Thank you.

1

0













CW
Cristofer Winter

1 INVESTMENTS

6 years ago

Hi Alice, fantastic platform! A few questions for you: (1) How are the experts on the platform recruited, vetted, and paid? (2) What are the other health verticals that you plan to expand into with this platform? (3) What percentage of users are repeat or regular users?

1

0













BZ
Barnaby Zelman

21 INVESTMENTS

6 years ago

At what valuation will your planned $5m Reg.A+ round be offered? Also, why not bump this offering up to the $1.07m maximum before looking at the A+ option?

1

0













MP
Michael Perkovich

6 years ago

How do you plan on growing the business and marketing the company?

1

0













MP
Michael Perkovich

6 years ago

Who is your competition and how do you compare to Kindara who is raising Series A very soon? Thanks

0

0

AC
Alice Crisci

MedAnswers

6 years ago

Hi Michael, Kindara, Glow, Ovia, Clue - those are fertility tracking apps. We are not a fertility tracking app. We could easily integrate with fertility tracking apps in the future. Kindara does not provide telehealth services. They help women monitor their monthly period, basal body temperature and other health details to find their most fertile window. We are building a widget to allow period tracking app users to ask our experts questions right from their fertility tracking device. We could also promote those apps within our infertility marketplace. Competitors they are not. Free Facebook groups are actually are biggest, direct competitors because women are already asking each other medical questions in private communities. No one else has created a free marketplace for infertility digitally but us. Our indirect competitors are mature telehealth companies like healthtap, amwell and even drondemand. Maven is a competitor in women's health but also a potential collaborator. None of those competitors have a global network of infertility experts like we do. Even though we are the first within infertility, we are not the first with our model. Hope that helps bring some clarity about the space. Thank you for asking your questions!

0

0

MP
Michael Perkovich

6 years ago

Appreciate the info. This platform sounds like something people can really benefit from. And with you adding additional areas in the future the growth potential seems apparent.

1

0













MP
Michael Perkovich

6 years ago

Last question, Alice. Are you currently profitable and generating revenue, or are all monies going back into the business?

1

0













MP
Michael Perkovich

6 years ago

How do you plan on generating revenue now and into the future?

2

0













HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$145,702.50
INVESTORS
88
MIN INVEST
VALUATION

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.